Tumors utilize aerobic glycolysis to support growth and invasion. However, the molecular mechanisms that link metabolism with invasion are not well understood. The nutrient sensor O-linked-β-N-acetylglucosamine (O-GlcNAc) transferase (OGT) modifies intracellular proteins with N-acetylglucosamine. Cancers display elevated O-GlcNAcylation and suppression of O-GlcNAcylation inhibits cancer invasion and metastasis. Here, we show that the regulation of cancer invasion by OGT is dependent on the NAD + -dependent deacetylase SIRT1. Reducing O-GlcNAcylation elevates SIRT1 levels and activity in an AMPK (AMP-activated protein kinase α)-dependent manner. Reduced O-GlcNAcylation in cancer cells leads to SIRT1-mediated proteasomal degradation of oncogenic transcription factor FOXM1 in an MEK/ERK-dependent manner. SIRT1 is critical for OGT-mediated regulation of FOXM1 ubiquitination and reducing SIRT1 activity reverses OGT-mediated regulation of FOXM1. Moreover, we show that SIRT1 levels are required for OGT-mediated regulation of invasion and metastasis in breast cancer cells. Thus, O-GlcNAcylation is a central component linking metabolism to invasion and metastasis via an SIRT1/ERK/FOXM1 axis.
INTRODUCTION
Cancer cells increase nutrient consumption leading to the altered metabolic state known as the Warburg effect. 1, 2 The Hexosamine Biosynthetic Pathway utilizes major metabolic pathways including glucose, amino acid, fatty acid and nucleotide metabolism to generate the nucleotide sugar uridine diphosphate N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc is used as a substrate for glycosylation of proteins including the post-translational addition of O-linked-β-N-acetylglucosamine (O-GlcNAc) on nuclear and cytosolic proteins, by the enzyme O-GlcNAc transferase (OGT). 3 This modification can be removed by the glycoside hydrolase O-GlcNAcase (OGA) that catalyzes cleavage of O-GlcNAc from proteins. 4 This modification can alter protein function directly or, in some cases, indirectly by competing with phosphorylation sites. 5 More recently, elevated O-GlcNAcylation has been described in various types of cancer. 6 Our laboratory provided the first evidence that breast 7 and prostate 8 cancers increase total O-GlcNAcylation by increasing OGT levels. O-GlcNAcylation has been found to be elevated in a host of other cancers including epithelial tumors of the lung, 9 liver 10 and colon. 11 We have recently shown that the mTOR/MYC pathway can increase OGT levels and O-GlcNAcylation in breast cancer cells 12 thus providing a potential explanation as to why multiple tumor types contain increased O-GlcNAcylation and OGT levels. We have also demonstrated that suppressing O-GlcNAcylation in breast cancer cells leads to reversal of the Warburg effect via regulation of metabolic regulator hypoxia-inducible factor-1α. 13 Importantly, reducing OGT activity inhibits cancer cell invasion in vitro 7 and metastasis in vivo. 8, 14 However, the mechanism by which O-GlcNAcylation regulates invasion and metastasis remains unclear.
The oncogenic transcription factor FOXM1 is increased in invasive cancer cells and tissues and is considered as a signature of invasive tumor behavior and poor clinical outcomes. 15 In response to growth factor stimulation, cancer cells stabilize FOXM1 levels to promote cell-cycle progression, proliferation and invasion. 16, 17 FOXM1 has been shown to be directly phosphorylated, stabilized and activated by ERK. 17 We have previously shown that OGT inhibition reduces breast and prostate cancer cell invasion through, in part, inhibition of the oncogenic transcription factor, FOXM1 and two of its transcriptional targets, notably the matrix metalloproteinases 2 and 9 (MMP2, MMP9). 7, 8 However, the mechanism by which OGT regulates FoxM1 remains unclear.
The sirtuins or class III NAD + -dependent deacylases have been implicated in many physiological functions including metabolism and cancer. 18, 19 Activation of SIRT1 has been shown to extend the life span and promote health in a variety of organisms including yeast and mammals. 20, 21 Emerging evidence also points to SIRT1 as a critical player in tumor suppression. 22, 23 Tissue-specific loss of SIRT1 is reported to be associated with the increased growth of tumors of the breast, 24 colon 22 and liver. 21 Recently, SIRT1 was shown to prevent epithelial-to-mesenchymal transition, invasion and metastasis of breast cancer cells via inhibition of MMP levels. 25 Here, we demonstrate that the nutrient sensing pathway Hexosamine Biosynthetic Pathway connects with the SIRT1 deacetylase via O-GlcNAcylation to regulate cellular invasion via regulation of FOXM1.
O-GlcNAcylation inhibits glycolysis in cancer cells. 13 As reprogramming of cellular metabolism alters intracellular NAD(+) levels, 26 we examined the effects on NAD + metabolites upon alteration of O-GlcNAcylation in cancer cells. MDA-MB-231 breast cancer cells stably expressing OGT shRNA displayed a significant increase in the ratio of NAD + /NADH metabolite levels compared with control cells (Supplementary Figure S1A) . As SIRT1 is a NAD +dependent deacetylase regulated by changes in energy metabolism, 18 we hypothesized that OGT could be regulating SIRT1 levels in breast cancer cells. We examined SIRT1 expression in the context of altered OGT/O-GlcNAcylation in a panel of breast cancer cell lines. MDA-MB-231 breast cancer cells stably expressing OGT shRNA ( Figure 1a ) contained 2-to 2.5-fold increase levels of SIRT1 (Supplementary Figure S1B ), and increased activity as measured by reduced acetylation of p53 on K382 (Figure 1a) , an SIRT1-specific target. 27 To ensure effect on SIRT1 levels and activity was dependent on O-GlcNAc cycling, we treated MDA-MB-231 cells with OGT inhibitor (Ac-5SGlcNAc) and also detected a 2.5-fold increase in SIRT1 levels and activity (Figure 1b , Supplementary Figure S1C ). Similar elevation in SIRT1 levels and activity was observed in other breast cancer cells including MCF-7 (Supplementary Figure S1D ) and MDA-MB-157 (Supplementary Figure S1E ) in response to reducing O-GlcNAcylation levels. Conversely, we observed reduced SIRT1 protein levels and activity when we elevated O-GlcNAcylation in MDA-MB-231 cells following treatment with OGA inhibitor NButGT (Figure 1c , Supplementary Figure S1F) or in MCF-7 cells stably overexpressing OGT (Figure 1d , Supplementary Figure S1G ). To test whether OGT regulates SIRT1 levels in vivo in non-tumorigenic tissue, we examined SIRT1 levels in mice containing ogt floxed alleles. We injected adenoviral (Ad)-Cre recombinase or Ad-GFP as a control into the mammary fat pads of female mice containing ogt exons flanked by loxP recombination sites. 28 To ensure that the majority of each fat pad was infected by adenovirus, we imaged mammary fat pads following Ad-GFP injection and found over 60% of the mammary gland positive for GFP (Supplementary Figure S1H ). Injecting Ad-Cre into mammary fat pad resulted in reduced OGT and O-GlcNAc levels and elevated SIRT1 levels compared with Ad-GFP-treated mice ( Figure 1e ). Thus, O-GlcNAcylation regulates SIRT1 levels in mammary tissue in vivo and also SIRT1 levels and activity in cancer cells.
O-GlcNAcylation regulation of SIRT1 protein levels requires the metabolic sensor AMPK-activated protein kinase α To understand how O-GlcNAcylation regulates SIRT1, we first examined whether O-GlcNAcylation regulates SIRT1 at the level of RNA. Although breast cancer cells expressing OGT RNA interference (RNAi) contain a 2-to 2.5-fold increase in SIRT1 protein levels (Figure 1a , Supplementary Figure S1B), these cells contain decreased levels of SIRT1 RNA as measured by quantitative RT-PCR (qRT-PCR) compared with control cells (Supplementary Figure S2A ). This indicated that OGT regulation of SIRT1 is independent of RNA and may be at the level of protein. We next examined whether O-GlcNAcylation could influence SIRT1 protein degradation. MDA-MB-231 cells were treated with either DMSO or OGA inhibitor and also treated with the proteasome inhibitor MG132. O-GlcNAc-mediated inhibition of SIRT1 was reversed by treatment with MG132 (Figure 2a , Supplementary Figure S2B ), suggesting that the change in SIRT1 protein levels was proteasome dependent. Consistent with this idea, we found that elevating O-GlcNAcylation in MDA-MB-231 cells, by treating with OGA inhibitor, decreased SIRT1 protein stability in cells incubated with cycloheximide compared with control treated cells (Supplementary Figure S2C and D). SIRT1 protein does not appear to be directly O-GlcNAcylated, as immunoprecipitatation with RL2 (O-GlcNAc antibody) did not pull down endogenous SIRT1 (Supplementary Figure S2E ) and exogenous Flag-tagged SIRT1 protein (Supplementary Figure S2F ) contained no detectable O-GlcNAcylation when compared with the positive control, the transcription factor Sp1 (Supplementary Figure S2E ). Although these data do not rule out that SIRT1 may be O-GlcNAcylated, it suggests that O-GlcNAcylation regulates SIRT1 protein stability possibly via an indirect mechanism.
OGT inhibition induces phosphorylation and activation of AMPactivated protein kinase α (AMPK). 13 As SIRT1-deacetylase activity has been shown to be regulated through activation of AMPK, 29, 30 we hypothesized that OGT/O-GlcNAcylation may regulate SIRT1 protein stability in an AMPK-dependent manner. To test this, MDA-MB-231 cells stably expressing control or OGT shRNA were treated with the AMPK inhibitor, Compound C. MDA-MB-231 cells treated with Compound C contained decreased AMPK phosphorylation and activation as measured by phosphorylation of its substrate Raptor (Ser792) ( Figure 2b ). The increased SIRT1 levels and activity observed upon suppression of OGT were reversed by treatment with Compound C compared with control cells (Figure 2b , Supplementary Figure S3A ). Similar results were obtained in MCF-7 (Supplementary Figure S3B ) and MDA-MB-157 (Supplementary Figure S3C ) breast cancer cells, suggesting that the regulation of SIRT1 by OGT was AMPK dependent in multiple breast cancer cells. Similar to our observation in cancer cell lines, wild-type mouse embryonic fibroblasts (MEFs) expressing OGT shRNA displayed increased SIRT1 levels compared with control cells (Figure 2c , Supplementary Figure S2G ). However, OGT-depleted MEFs containing deletion of both αlpha subunits of the AMPK gene (MEF-AMPKα − / − ) did not increase SIRT1 levels or activity upon OGT suppression (Figure 2c , Supplementary Figure S2G ). To test whether AMPK activation alone was sufficient to increase SIRT1 levels in MDA-MB-231 cells, we treated cells with AICAR (5-aminoimidazole-4-carboxamide-ribonucleotide), an AMP analog known to activate AMPK and increase phosphorylation of downstream AMPK targets including Raptor. 31 Treatment of cells with AICAR, as well as glucose deprivation, increased SIRT1 levels and increased both AMPK activation and Raptor phosphorylation. These changes were similar to those observed with OGT inhibitor treatment ( Figure 2d ) and consistent with previous results showing that increase in O-GlcNAcylation, via treatment with OGA inhibitor, inhibits AMPK activity. 13 To test whether OGT regulation of AMPK and SIRT1 is dependent on changes in metabolism, we tested whether treating OGT-depleted cells with methyl pyruvate, a permeable nutrient that supports bioenergetics, would reverse AMPK activation and SIRT1 levels. Reducing OGT levels in MDA-MB-231 cells leads to activation of AMPK as measured by an increase in Raptor phosphorylation (Supplementary Figure S3D ). However, this activation was reduced in OGT-depleted cells treated with methyl pyruvate compared with control cells (Supplementary Figure S3D ). SIRT1 levels were slightly increased in cells treated with methyl pyruvate compared with control. However, knocking down of OGT did not affect SIRT1 levels in the presence of methyl pyruvate, suggesting that OGT regulation of SIRT1 is, in part, dependent on metabolic changes. Consistent with reversing AMPK-associated signaling and metabolic stress, methyl-pyruvate treatment also reversed ATP level depletion in OGTknockdown cells (Supplementary Figure S3E ). Taken together, these results suggest that O-GlcNAcylation regulation of SIRT1 protein stability is dependent on the metabolic sensor AMPK in cancer cells and associated with O-GlcNAcylation regulation of cell metabolism.
O-GlcNAcylation-mediated cancer cell invasion requires SIRT1 regulation of FOXM1 signaling
We have previously shown that inhibition of OGT levels or activity reduces breast 7 and prostate 8 cancer cell invasion in vitro. SIRT1 activity has been shown to be critical in the regulation of epithelialto-mesenchymal transition and metastasis of breast cancer cells in vivo. 25 Therefore, we sought to characterize the role of SIRT1 in OGT-mediated breast cancer cell invasion. Reducing OGT expression in MDA-MB-231 cells blocks cellular invasion in a three-dimensional (3D) culture system ( Figure 3a Our laboratory has previously demonstrated that OGT-mediated invasion in breast and prostate cancer cells was associated with regulation of FOXM1 protein stability 7, 8 and its transcriptional targets MMP2 and MMP9. Therefore, we investigated effect on MMP2 and MMP9 by SIRT1 was indeed FOXM1 dependent. We were also able to reverse OGT depletion-mediated inhibition of FOXM1 and MMP9 levels (Supplementary Figure S5B ) and the invasive phenotype (Supplementary Figure S5C) in MDA-MB-231 cells after treatment with the SIRT1-specific inhibitor EX-527. Treatment of MDA-MB-231 cells with EX-527 had similar effects on p53 acetylation (Supplementary Figure S5B ) compared with cells containing SIRT1 knockdown (Figure 3c) . Conversely, overexpression of SIRT1 in MDA-MB-231 breast cancer cells resulted in reduced expression of FOXM1 as well as that of its transcriptional targets MMP2 and MMP9 (Figure 3d ) and was also consistent with concomitant decreases in cellular invasion (Figure 3e ). Thus, these data suggest that OGT regulation of the key cell invasion protein FOXM1 and its targets MMP2 and MMP9 in breast cancer cells is dependent on O-GlcNAc suppression of SIRT1.
SIRT1 regulates FOXM1 ubiquitination and proteasomal degradation via D and KEN boxes and E3-ubiquitin ligase Cdh1
As we were unable to detect SIRT1-dependent acetylation changes on FOXM1 (data not shown), we hypothesized that SIRT1 may be regulating FOXM1 activity via an alternate mechanism. To test whether SIRT1 regulates FOXM1 degradation, MDA-MB-231 cells treated with the SIRT1-specific activator, SRT1720, 32 were subjected to proteasome inhibition using MG132. Downregulation of FOXM1 protein levels upon SIRT1 activation could be reversed by treatment with MG132 (Figure 4a ), suggesting that SIRT1 regulation of FOXM1 was proteasome dependent. We also detected a 1.5-fold increase in FOXM1 ubiquitination under conditions of decreased OGT levels in MDA-MB-231 cells compared with controls ( Figure 4b ). However, this OGT-mediated increase in FOXM1 ubiquitination was diminished in the presence of SIRT1 shRNA (Figure 4b ). The N-terminus of FOXM1 contains degron destruction D-box and KEN-box sequences that are known to be essential for FOXM1 degradation. 33 As OGT regulates FOXM1 proteasome-mediated degradation via the D-box and KEN-box sequences, 7 we investigated whether SIRT1 activation reduces FOXM1 levels in MDA-MB-231 cells stably expressing either wild-type or a degradation-resistant FoxM1 mutant. Treatment with SIRT1 activator SRT1720 resulted in decreased levels of exogenous wild-type FOXM1 and its target MMP9 in MDA-MB-231 cells (Figure 4c, Supplementary Figure S5D ). However, in MDA-MB-231 cells overexpressing the non-degradable FoxM1 mutant lacking the N-terminus, SIRT1 activation did not alter levels of FOXM1 mutant or MMP9 levels compared with wild-type FOXM1-expressing cells (Figure 4c ). As the E3-ubiquitin ligase Cdh1 is known to regulate the FOXM1 degradation pathway, 34 we examined whether SIRT1 effects on FOXM1 were dependent on Cdh1-mediated degradation. We compared the effects of SIRT1 overexpression on FOXM1 levels in HEK293T cells stably expressing control or Cdh1 RNAi. Reducing levels of Cdh1 increased endogenous expression of FOXM1 levels (Figure 4d ). Overexpression of SIRT1 in breast cancer cells (Figure 3d ) or in HEK293T cells reduced levels of FOXM1 (Figure 4d ). This inhibition was lost in HEK293T cells containing Cdh1 stable RNAi compared with control cells (Figure 4d ). Taken together, these data suggest that the regulation of FOXM1 by OGT requires SIRT1mediated ubiquitination and proteasomal degradation of FOXM1, which is dependent on its D-box/KEN-box degron domains and its E3-ligase Cdh1.
O-GlcNAc/SIRT1 regulation of FOXM1 requires the MEK/ERK pathway in breast cancer cells
Growth factor-dependent stabilization of FOXM1 protein can be mediated through ERK phosphorylation to promote an invasive signature in various cancer types. 16, 17 Recent reports have demonstrated that SIRT1 can inhibit MAP-Kinase pathway activity through direct deacetylation of MEK, thus affecting its ability to phosphorylate and activate ERK. 35 Therefore, we sought to investigate whether O-GlcNAc and SIRT1 could promote FOXM1 stability via the MEK-ERK pathway. To address this question, we first measured levels of ERK phosphorylation (Thr202/Tyr204) in OGT-depleted cells with and without stable expression of SIRT1 RNAi. Depletion of OGT levels reduced ERK phosphorylation in MDA-MB-231 (Figure 5a, Supplementary Figure S6A ), MDA-MB-468 (Supplementary Figure S6B) and MDA-MB-157 (Supplementary Figure S6C ) breast cancer cells. Changes in ERK phosphorylation upon OGT depletion were reversed in SIRT1-depleted cells in all three breast cancer cell lines, MDA-MB-231 (Figure 5a , Supplementary Figure S6A ), MDA-MB-468 (Supplementary Figure S6B ) and MDA-MB-157 ( Supplementary Figure S6C) , indicating that OGT-mediated regulation of ERK is SIRT1 dependent. Consistent with these data, treating MDA-MB-231 cells with SIRT1 activator EX-527 also increased basal ERK activation but also reversed OGT-depleted inhibition of ERK activity (Supplementary Figure S6D ). Conversely, MDA-MB-231 cells treated with SIRT1 activator SRT1720 reduced ERK activity (Supplementary Figure S6E ), FOXM1 levels ( Figure 4c ) and invasion in 3D culture (Supplementary Figure S6F ). To test whether SIRT1 regulation of FOXM1 stability requires activation of MEK/ERK pathway, MDA-MB-231 cells were treated with the MEK inhibitor, U0126. As previously shown, cells depleted of SIRT1 display elevated FOXM1 levels and ERK activity compared with control cells (Figure 5b ). However, treatment of SIRT1-depleted cells with U0126 abrogated changes in FOXM1 levels (Figure 5b, Supplementary Figure S6G ) and decreased levels of the FOXM1 transcriptional target MMP9 (Figure 5b ). Consistent with reduced FOXM1 and MMP9 levels, SIRT1-depleted MDA-MB-231 cells treated with MEK inhibitor mitigated cellular invasion ( Figure 5c ) and invasion in 3D culture (Figure 5d ). Finally, to test whether SIRT1 regulation of ERK/FOXM1 pathway occurs in noncancer cells, we examined FOXM1 levels and ERK activation in SIRT1-deficient (SIRT1 − / − ) MEFs compared with wild-type MEFs. Figure S6H) . These data indicate that OGT-mediated increase in SIRT1 levels and activity can suppress ERK signaling leading to reduction of FOXM1 activity and invasion in aggressive breast cancer cells.
SIRT1-deleted MEFs contained higher FOXM1 levels and ERK activation compared with control cells (Supplementary

SIRT1 is critical for OGT-mediated regulation of breast cancer metastasis in vivo
On the basis of our in vitro studies above, we hypothesized that OGTs regulation of metastasis may involve modulating SIRT1 levels in breast cancer cells. To test directly whether OGT regulation of SIRT1 has a critical role in breast cancer metastasis, we compared the effects of OGT knockdown in an intracardiac model of metastasis in MDA-MB-231 cells stably expressing control or SIRT1 RNAi. MDA-MB-231 cells expressing luciferase and either control shRNA or OGT shRNA in the presence or absence of SIRT1 shRNA ( Figure 6A) were injected into the left ventricle of female NSG mice. The progression of systemic metastasis of tumor cells following intracardiac injection was monitored by bioluminescence imaging using a stably expressed firefly luciferase reporter. Reducing OGT in MDA-MB-231 cells caused a decrease in metastatic dissemination in vivo ( Figure 6B ) and decreased establishment of liver macrometastasis ( Figure 6C ) and micrometastasis ( Figure 6D ). However, cells depleted of SIRT1 were able to rescue the metastatic effect of OGT RNAi in vivo ( Figure 6B ), as SIRT1 RNAi in the context of OGT depletion reversed liver macrometastasis ( Figure 6C ) and significantly reversed micrometastasis ( Figure 6D ) compared with control OGT-depleted cells. Consistent with bioluminescence imaging, histological sections from the control shRNA group exhibited massive liver metastatic tumor (Figure 6Ea ). By comparison, a striking decrease in the size and intrahepatic spread of metastatic cancer deposits was demonstrated in OGT-depleted MDA-MB-231 cells (Figure 6Eb ). In contrast, widespread metastatic involvement accompanied by tumor necrosis, comparable in severity to the control group, was detected in the SIRT1 shRNA group (Figure 6Ec ), as well as in the OGT shRNA group albeit in the presence of SIRT1 shRNA (Figure 6Ed) . Thus, at the histological level, inhibition of hepatic metastasis by OGT depletion could be reversed in the presence of SIRT1 shRNA. Similar results were seen in histological analysis of bone metastasis to vertebral column (Supplementary Figure S7) . Thus, OGT regulation of cancer metastasis in vivo is partly dependent on SIRT1 expression.
DISCUSSION
Taken together, our findings have demonstrated a novel mechanism by which the nutrient sensor, O-GlcNAcylation contributes to the acquisition of invasive and metastatic phenotypes in breast cancer cells through regulation of SIRT1/FOXM1 axis. For the first time, we demonstrate that SIRT1 inhibits stability of the oncogenic transcription factor FOXM1 effectively suppressing tumor cell invasion and provide a mechanism by which reduced SIRT1 levels may contribute to metastasis. Recently, we have demonstrated that O-GlcNAcylation promotes a Warburg phenotype to alter metabolic signaling and energy status in cancer cells. 13 Our data strongly suggest a model (Supplementary Figure S8) in which OGT-mediated alterations in the energy metabolism can regulate AMPK signaling which regulates SIRT1 levels and activity in breast cancer cells. O-GlcNAcylation regulation of SIRT1 contributes to the stabilization of the oncogenic transcription factor FOXM1 via an ERK-dependent mechanism to regulate MMP2 and MMP9 levels and thus breast cancer invasion and metastasis. Collectively, these results establish a novel molecular pathway linking the metabolic regulator O-GlcNAcylation to invasion and metastasis via an SIRT1/ERK/FOXM1 axis.
Cross-talk between O-GlcNAcylation and the AMPK is emerging as an important node in regulating cell metabolism, growth and signaling in both normal physiology and diseased states Previous studies have shown that AMPK can phosphorylate OGT and regulate its substrate specificity and that AMPKα and γ subunits can be O-GlcNAcylated in skeletal muscle cells. 36 In cancer cells, our data suggest that O-GlcNAcylation regulates AMPK indirectly via regulation of metabolism. Reducing O-GlcNAcylation in cancer cells leads to a robust increase in AMPK activity that can be reversed by addition of a permeable nutrient metabolite to support bioenergetics such as methyl pyruvate or overexpressing glucose transporter GLUT1. 13 Interestingly, OGT encodes three splice variants with the longest OGT isoform nucloecytoplasmic OGT being localized in the nucleus and cytoplasm. 37, 38 This isoform has been linked to transcriptional regulation, proteasomal regulation and stress response. A mitochondrial isoform is thought to be proapoptotic. Future studies will determine which OGT isoform is a key regulator of AMPK, SIRT1 and metabolic pathways in cancer cells.
SIRT1 has a predominately tumor suppressing function in various tumor mouse models, including mice with mutant p53 39 or BRCA1. 24 It is possible that the role of SIRT1 in breast cancer may be dependent on genetic make-up or breast cancer subtype, as our data show that SIRT1 functions as a tumor suppressor in basal/triple-negative breast cancers. A decrease in SIRT1 levels caused reversal of the mitigating effect on metastatic potential of OGT-depleted cells, thus suggesting that reduced SIRT1 levels and activity are beneficial to metabolically stressed cancer cells and contribute to metastatic dissemination. SIRT1 also directly regulates transcription and chromatin silencing through deacetylation of histone substrates, 40 as well as a variety of non-histone targets involved in cancer including p53 and PGC-1α to combat cellular stress and promote oxidative metabolism. 41 Interestingly, O-GlcNAcylation is also known to regulate transcription and epigenetic regulators. 42 It will be of interest to determine whether an inverse relationship exists between genes regulated by O-GlcNAcylation and SIRT1. It was recently demonstrated that in response to growth factor stimulation, SIRT1 can directly deacetylate MEK (K175) to inhibit downstream ERK activation. 35 In addition, it was recently shown that SIRT2 depletion in colon and lung cancer cells increases activation of ERK signaling and leads to resistance to epidermal growth factor receptor inhibitors. 43 Our studies are consistent with these data and extend a role of SIRT1/ERK signaling to regulate oncogenic transcription factor FOXM1, which is critical for invasion and metastasis in aggressive breast cancer cells.
Complete knockout of OGT in MEFs leads to defects in cell growth; 28 and other studies have shown that O-GlcNAcylation is important in cell-cycle progression. 38 Our studies and others suggest that knockdown of OGT or pharmacological inhibition of O-GlcNAcylation impairs growth and survival of cancer cells, but has no effect on non-transformed epithelial cells of the prostate, 8 mammary 7,12 and pancreas. 44 These data suggest that cancer cells may be more dependent on O-GlcNAcylation for growth and survival compared with normal counterparts. However, developing specific OGT inhibitors may help address this important question.
Activity of sirtuins, including SIRT1, has been reported to decrease during aging and is associated with altering longevity. 18, 45 Interestingly, recent reports have shown that various tissues derived from aging mice contain elevated levels of O-GlcNAcylation. 46, 47 As we have shown that reducing O-GlcNAcylation in normal mammary tissue increases SIRT1 levels in vivo, it will be interesting to further understand the inverse relationship between O-GlcNAcylation and SIRT1 as it relates to aging and longevity in future studies. Thus, aberrant O-GlcNAcylation contributes to cancer progression via regulation of SIRT1 and may also connect to pathways associated with aging and longevity.
MATERIALS AND METHODS Reagents
NButGT and Ac-5SGlcNAc were provided by D Vocadlo (Simon Fraser University). 48 SRT1720, EX-527 and Compound C purchased from Selleck-Chemicals (Houston, TX, USA). MG132 purchased from Sigma-Aldrich (St Louis, MO, USA). pcDNA3.1-SIRT1-Flag was a gift from E Verdin (Addgene plasmid#: 13812). pLenti4-HA-OGT was provided by K Vosseller (Drexel University). Antibodies used were anti-actin, anti-FOXM1 and anti-RL2 from Santa Cruz Biotechnology (Dallas, TX, USA); pERK1/2, anti-OGT and anti-O-GlcNAc from Sigma-Aldrich; anti-acetylated p53(K382), anti-AMPK, anti-pAMPK(S172), anti-ERK1/2, anti-MMP2, anti-pRaptor(792), anti-Raptor, anti-SIRT1 and anti-Ubiquitin(K48) from Cell Signaling (Danvers, MA, USA); anti-Cdh1 and anti-p53 from Neobiolabs (Woburn, MA, USA); anti-MMP9 from Novus-Biologicals (Littleton, CO, USA); and integrin α5 and α6 are from BD-Pharmingen (San Jose, CA, USA).
Cell culture
MDA-MB-231, MDA-MB-157, MCF-7 and MDA-MB-468 cells were obtained from ATCC (Manassas, VA, USA) and cultured according to ATCC. SIRT1+/+ and SIRT1 − / − MEFs were cultured as previously described. 49 MEFs and AMPK null (AMPKα1/α2 KO) MEFs were kindly provided by B Viollet (INSERM) and cultured as previously described. 50 Metabolic assays NAD + /NADH levels were measured with the NAD/NADH Cell Based Assay Kit (Cayman Chemical, Ann Arbor, MI, USA); and ATP levels were measured with the ATP Assay Kit (Calbiochem, San Diego, CA, USA) according to the manufacturer's protocol.
Immunoblotting
Immunoblotting protocols have been previously described. 51 3D assay and indirect immunofluorescence Assays were performed as described previously. 7, 52 Immunoprecipitation Assays were performed as described previously. 13 Transwell invasion assays Invasion assays were performed as previously described. 8 Assays utilizing chemical inhibitors were performed by adding inhibitors at indicated concentrations before seeding.
shRNA generation shRNA sequences and lentiviral particles were generated as previously described. 7, 13 Sequences used for SIRT1 were MissionshRNA clones; SIRT1-1 (TRCN0000229630, Sigma-Aldrich) and SIRT1-2 (TRCN0000218734, Sigma-Aldrich).
Animal studies
Female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratory, Bar Harbor, ME, USA) (6-8 weeks old) were randomized and inoculated via intracardiac injection into the left ventricle with 2.0 × 10 5 MDA-MB-231 cells as previously described. 8 Mice were injected intraperitoneally with 200 μl of D-luciferin solution (9 mg/ml; Caliper-Life-Sciences, Hopkinton, MA, USA), and bioluminescence imaging was performed 4 h after intracardiac injection to detect the distribution of breast cancer cells followed by weekly imaging using the IVIS 200/Lumina XR from Caliper Life Sciences (Perkin Elmer, Waltham, MA, USA). Only animals that showed successful injections by bioluminescence were included in the analysis. Sample size was determined via previous analysis. B6.129-Ogt tm1Gwh /J females used for fat pad injections have been previously described 28 and were obtained as a kind gift from S Jones (University of Louisville). Mice were injected directly into the mammary fat pad with Ad5-CMV-GFP or Ad5-CMV-Cre (2.7 × 10 7 PFU, from the Baylor College of Medicine). Animals groups were not blinded. Histology was performed as previously described. 8 All animal protocols were approved by the Institutional Animal Care and Use Committee.
qRT-PCR
qRT-PCR was performed as previously described. 13 TaqMan gene expression assay primer/probes were purchased from Applied Biosystems (Foster City, CA, USA) for cyclophilin A (Hs99999904_m1), OGT (Hs00914634_g1), SIRT1 (Hs01009005_m1) and MMP9 (Hs00234579_m1).
Statistics
All results shown are results of at least three independent experiments and shown as averages and presented as mean ± s.e. P-values were calculated using a Student's two-tailed test (* represents at least P-value o 0.05). Where indicated, one-way ANOVA was used to compare differences between multiple groups (** represents at least P-value o0.05). Appropriate sample size was chosen to achieve significance using this analysis.
